Subject
Tool
Region
FOUND 5
This study demonstrated the safety and efficacy of the dapvirine vaginal ring, as well as oral PrEP regimens with tenofovir disoproxil fumarate and emtricitabine, for use during pregnancy. The safety of the oral PrEP methods has previously been established for pregnant cisgender women, but data has been limited for the dapivirine ring. This represents an important step for reducing HIV infection amongst pregnant women, who are three times more…
Lenacapavir, a twice-yearly injectable PrEP medication, was proven to be completely effective in preventing HIV infection in cisgender women. Developed by Gilead Sciences, this is the first HIV prevention drug that resulted in zero new human infections during Phase 3 trials. Lenacapavir holds great promise for the future of HIV prevention, as it represents an alternative that can mitigate challenges of adherence and stigma associated with a…
This technical guide is intended to support countries in their efforts to increase their capacity to eliminate mother-to-child transmission of HIV in prison, and achieve the ultimate goal of ending AIDS as a public health threat by 2030, “leaving no one behind”.
Despite the importance of women living with HIV (WLHIV) engaging in fertility plan discussions with their healthcare providers (HCPs), little research exists. This study explored perceptions surrounding fertility plan discussions between WLHIV and their HCPs in western Ethiopia, from the perspectives of both women and providers
UNAIDS report on the global AIDS pandemic 2020 shows that women and girls in sub-Saharan Africa continue to be the most affected and accounted for 59% of all new HIV infections in the region in 2019, with 4500 adolescent girls and young women between 15 and 24 years old becoming infected with HIV every week. Young women accounted for 24% of new HIV infections in 2019, despite making up only 10% of the population in sub-Saharan Africa.